OGEN Oragenics 8-K2021Oragenics Enters into Material Transfer Agreement with Adjuvance Technologies for COVID-19 Vaccine Adjuvant
7 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
OGEN 8-K Filings
- 14 Jan 21 Oragenics Issues Letter to Stockholders
- 7 Jan 21 Oragenics Enters into Material Transfer Agreement with Adjuvance Technologies for COVID-19 Vaccine Adjuvant
- 29 Dec 20 Oragenics Announces Closing of $6.5 Million Registered Direct Offering
- 28 Dec 20 Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
- 24 Nov 20 Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…